These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11196 related articles for article (PubMed ID: 1396075)

  • 61. [A randomized control study on the clinical effects of ramosetron in prophylaxis of nausea and vomiting induced by cisplatin chemotherapy in patients with lung cancer].
    Yang X; Zhang S
    Zhongguo Fei Ai Za Zhi; 2005 Aug; 8(4):322-5. PubMed ID: 21108892
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.
    Herrstedt J; Summers Y; Daugaard G; Christensen TB; Holmskov K; Taylor PD; Fox GM; Molassiotis A
    Support Care Cancer; 2018 Jan; 26(1):139-145. PubMed ID: 28801850
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
    Kris MG; Clark RA; Tyson LB; Hahne WF; Pisters KM; Gralla RJ
    Am J Clin Oncol; 1993 Feb; 16(1):77-80. PubMed ID: 8424410
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
    Grunberg SM; Lane M; Lester EP; Sridhar KS; Mortimer J; Murphy W; Sanderson PE
    Cancer Chemother Pharmacol; 1993; 32(4):268-72. PubMed ID: 8324868
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
    Beck TM; York M; Chang A; Navari R; Harvey WH; Meshad M; Griffin D; Wentz A
    Cancer Invest; 1997; 15(4):297-303. PubMed ID: 9246149
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32-mg loading dose versus 8 mg every 6 h in patients undergoing cisplatin-based chemotherapy.
    Tsavaris N; Fountzilas G; Mylonakis N; Athanassiadis A; Kosmas C; Karakousis C; Bacoyiannis C; Kosmidis P
    Oncology; 1998; 55(6):513-6. PubMed ID: 9778615
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
    Sledge GW; Einhorn L; Nagy C; House K
    Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation.
    Osowski CL; Dix SP; Lynn M; Davidson T; Cohen L; Miyahara T; Sexauer MC; Joyce R; Yeager A; Wingard JR
    Support Care Cancer; 1998 Nov; 6(6):511-7. PubMed ID: 9833299
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Improved control of emesis and quality of life with ondansetron in breast cancer.
    Clavel M; Soukop M; Greenstreet YL
    Oncology; 1993; 50(3):180-5. PubMed ID: 8459989
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation.
    Spitzer TR; Bryson JC; Cirenza E; Foelber R; Wallerstadt M; Stout C; Kunka RL; Plagge PB; Dubois A
    J Clin Oncol; 1994 Nov; 12(11):2432-8. PubMed ID: 7964960
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
    Legha SS; Hodges C; Ring S
    Cancer; 1992 Oct; 70(7):2018-20. PubMed ID: 1388090
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of three preclinical models for nausea and vomiting assessment.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo.
    Gandara DR; Harvey WH; Monaghan GG; Perez EA; Hesketh PJ
    Eur J Cancer; 1993; 29A Suppl 1():S35-8. PubMed ID: 8427724
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
    Liaw CC; Chang HK; Liau CT; Huang JS; Lin YC; Chen JS
    Am J Clin Oncol; 2003 Feb; 26(1):12-5. PubMed ID: 12576917
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of tumour burden on chemotherapy-induced nausea and vomiting.
    Hursti TJ; Avall-Lundqvist E; Börjeson S; Fredrikson M; Fürst CJ; Steineck G; Peterson C
    Br J Cancer; 1996 Oct; 74(7):1114-9. PubMed ID: 8855984
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
    Hebbar M; Hecquet B; Vanlemmens L; Lecomte S; Pion JM; Adenis A; Bonneterre J
    Bull Cancer; 1995 Jan; 82(1):67-9. PubMed ID: 7742620
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.
    Franzén L; Nyman J; Hagberg H; Jakobsson M; Sorbe B; Nyth AL; Lomberg H; Henriksson R
    Ann Oncol; 1996 Aug; 7(6):587-92. PubMed ID: 8879372
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma].
    Campora E; Simoni C; Rosso R
    Minerva Med; 1994; 85(1-2):25-31. PubMed ID: 8152575
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of anti-emetic use in chemotherapy-induced nausea and vomiting in a third-world country (Lebanon).
    Zeitoun AA; Nassif JG
    J Eval Clin Pract; 2013 Feb; 19(1):68-75. PubMed ID: 21999252
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2.
    Brock P; Brichard B; Rechnitzer C; Langeveld NE; Lanning M; Söderhäll S; Laurent C
    Eur J Cancer; 1996 Sep; 32A(10):1744-8. PubMed ID: 8983284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 560.